Zhao Jingjing, Liu Huahua, Xu Buyun, Peng Jiahao, Xing Yangbo, Tang Weiliang, Peng Fang
Department of Cardiology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, China.
Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China.
Evid Based Complement Alternat Med. 2020 Apr 27;2020:5419016. doi: 10.1155/2020/5419016. eCollection 2020.
This study aimed to investigate the effect of Xuefu Zhuyu decoction on preventing contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI).
A total of 256 patients undergoing selective PCI for coronary artery disease were consecutively enrolled and randomly divided into two groups: Group A ( = 126) and Group B ( = 130). Before and after PCI, all patients routinely received antiplatelet aggregation therapy, antilipidemic therapy, and hydration therapy. Besides routine therapy, patients in Group B received Xuefu Zhuyu decoction from 3 days before PCI to 3 days after PCI. Serum creatinine (Scr), estimated glomerular filtration rate (eGFR), superoxide dismutase (SOD), and malondialdehyde (MDA) were measured, respectively, at baseline (72 h before PCI) and at 24, 48, and 72 h after PCI.
Compared with Group A, Group B presented a lower fluctuation of SCr and eGFR ( < 0.01). The incidence of CIN was less in Group B. According to the definition, CIN occurred in 5 patients (2.0%) in the intervention group and 5 (4.0%) in the control group (=0.167). In terms of oxidative stress, Group B had a lower MDA ( < 0.05), but a higher SOD ( < 0.05).
Compared with the control group, Xuefu Zhuyu decoction intervention therapy increased the level of SOD and reduced MDA. The Xuefu Zhuyu decoction intervention group presented a higher level of eGFR at 24, 48, and 72 h after PCI in patients with coronary heart disease and a lower level of Scr. The results are propitious to prove that Xuefu Zhuyu decoction might play an antioxidative stress role in the prevention of CIN after PCI.
本研究旨在探讨血府逐瘀汤对经皮冠状动脉介入治疗（PCI）后预防对比剂肾病（CIN）的作用。
连续纳入256例因冠状动脉疾病接受选择性PCI的患者，并随机分为两组：A组（n = 126）和B组（n = 130）。PCI前后，所有患者常规接受抗血小板聚集治疗、降脂治疗和水化治疗。除常规治疗外，B组患者在PCI前3天至PCI后3天服用血府逐瘀汤。分别在基线（PCI前72小时）以及PCI后24、48和72小时测量血清肌酐（Scr）、估计肾小球滤过率（eGFR）、超氧化物歧化酶（SOD）和丙二醛（MDA）。
与A组相比，B组Scr和eGFR的波动较小（P < 0.01）。B组CIN的发生率较低。根据定义，干预组有5例患者（2.0%）发生CIN，对照组有5例（4.0%）（P = 0.167）。在氧化应激方面，B组MDA较低（P < 0.05），但SOD较高（P < 0.05）。
与对照组相比，血府逐瘀汤干预治疗可提高SOD水平并降低MDA。血府逐瘀汤干预组冠心病患者在PCI后24、48和72小时的eGFR水平较高，Scr水平较低。结果有利于证明血府逐瘀汤在预防PCI后CIN中可能发挥抗氧化应激作用。
